SynthesisVox sanguinis2026
What is the impact of whole-blood donation frequency on donor health? A systematic review.
Synthesis in Vox sanguinis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
BACKGROUND AND
objectivesTo maintain a stable blood supply while protecting donor and recipient health, the World Health Organization (WHO) recommends minimum inter-donation intervals of 12 weeks for men and 16 weeks for women. These recommendations are merely based on observational studies reporting reduced haemoglobin (Hb) and iron levels and increased deferrals in repeat donors. This systematic review aims to examine the best available experimental evidence on how whole-blood donation frequency impacts donor health. MATERIALS AND
methodsPubMed (Medline, PMC and NCBI Bookshelf), Embase and the Cochrane Library were systematically searched by two reviewers independently. Risk of bias and certainty of evidence were evaluated using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach.
resultsFour records on three randomized controlled trials (RCTs) were included. The results showed that donating every 12 weeks may reduce Hb and ferritin levels compared to not donating. Similarly, shortening inter-donation intervals (from 12 to 8 or 10 weeks for men and from 16 to 12 or 14 weeks for women) may lead to decreased Hb and ferritin levels, increased low-Hb deferral and increased reporting of tiredness, fainting, dizziness and restless legs. Evidence was of low to very low certainty, and limitations in study design and imprecision prohibit strong recommendations on optimal inter-donation intervals.
conclusionIn the absence of more robust evidence and pending future high-quality RCTs, it is prudent to adhere to the current WHO guidelines on minimum inter-donation intervals for whole-blood donation, that is, 12 weeks for men and 16 weeks for women, as a precautionary measure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.